X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
oncology (38) 38
female (36) 36
middle aged (28) 28
adult (27) 27
breast cancer (24) 24
index medicus (23) 23
aged (22) 22
breast neoplasms - genetics (18) 18
breast neoplasms - pathology (15) 15
cancer (13) 13
breast neoplasms - drug therapy (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
male (11) 11
risk (11) 11
care and treatment (8) 8
chemotherapy (8) 8
women (8) 8
aged, 80 and over (7) 7
athletic recruitment (7) 7
cohort studies (7) 7
college football (7) 7
expression (7) 7
genetic aspects (7) 7
analysis (6) 6
article (6) 6
breast neoplasms - metabolism (6) 6
health aspects (6) 6
neoplasms - drug therapy (6) 6
prognosis (6) 6
tumors (6) 6
antineoplastic agents - adverse effects (5) 5
antineoplastic agents - pharmacokinetics (5) 5
breast neoplasms - surgery (5) 5
clinical trials (5) 5
diagnosis (5) 5
disease-free survival (5) 5
gene expression (5) 5
neoplasm recurrence, local - prevention & control (5) 5
phenotype (5) 5
prospective studies (5) 5
research (5) 5
risk factors (5) 5
survival (5) 5
tamoxifen (5) 5
abridged index medicus (4) 4
age factors (4) 4
age of onset (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic agents, hormonal - therapeutic use (4) 4
brca1 (4) 4
breast (4) 4
breast neoplasms - therapy (4) 4
camptothecin - analogs & derivatives (4) 4
cancer therapies (4) 4
cell lung-cancer (4) 4
chemotherapy, adjuvant (4) 4
drug administration schedule (4) 4
endocrine therapy (4) 4
erbb-2 protein (4) 4
genes, brca1 (4) 4
genes, brca2 (4) 4
genetic predisposition to disease (4) 4
genetic testing (4) 4
hematology, oncology and palliative medicine (4) 4
mastectomy (4) 4
medical research (4) 4
multidisciplinary sciences (4) 4
mutation (4) 4
neoplasm metastasis (4) 4
neoplasm recurrence, local (4) 4
neoplasm recurrence, local - genetics (4) 4
ovarian-cancer (4) 4
paclitaxel - administration & dosage (4) 4
radiation (4) 4
recurrence (4) 4
skin and connective tissue diseases (4) 4
therapy (4) 4
time factors (4) 4
treatment outcome (4) 4
adjuvant chemotherapy (3) 3
adjuvant treatment (3) 3
age (3) 3
alleles (3) 3
american society (3) 3
animals (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
atp-binding cassette, sub-family b, member 1 - metabolism (3) 3
base sequence (3) 3
biomedicine (3) 3
breast neoplasms - epidemiology (3) 3
breast neoplasms - psychology (3) 3
cancer patients (3) 3
carcinomas (3) 3
careers (3) 3
cells (3) 3
deaths (3) 3
dna topoisomerases, type i - blood (3) 3
dose-response relationship, drug (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 111 - 121
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 21, pp. 2005 - 2014
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 759 - 769
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 397 - 404
Abstract Background Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II... 
pembrolizumab | triple-negative breast neoplasms | anti-PD-1 | immunotherapy | ONCOLOGY | PD-L1 EXPRESSION | ANTIBODY
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69851
Several epidemiological studies have suggested a link between melanoma and breast cancer. Metabotropic glutamate receptor 1 (GRM1), which is involved in many... 
COMMON VARIANTS | SIGNALING PATHWAYS | GENETIC POLYMORPHISMS | MUTATION CARRIERS | GLUTAMATE-RECEPTOR-1 | MULTIDISCIPLINARY SCIENCES | RISK | PROLIFERATION | SUSCEPTIBILITY LOCUS | BRCA1 | GRM1 | Demography | Tissue Array Analysis | Humans | Middle Aged | Receptors, Metabotropic Glutamate - metabolism | Incidence | Neoplasm Recurrence, Local - pathology | Young Adult | Neoplasm Metastasis | Receptors, Metabotropic Glutamate - genetics | Aged, 80 and over | Adult | Estrogen Receptor alpha - metabolism | Female | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Estradiol - pharmacology | Breast Neoplasms - epidemiology | Breast Neoplasms - classification | Genetic Predisposition to Disease | Genetic Association Studies | Disease-Free Survival | Phenotype | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Tamoxifen - pharmacology | Polymorphism, Single Nucleotide - genetics | Tamoxifen - analogs & derivatives | Neoplasm Recurrence, Local - genetics | Aged | Cell Proliferation - drug effects | Cohort Studies | Oncology, Experimental | Genes | Estrogen | Melanoma | Amino acids | Breast cancer | Research | Tamoxifen | Glutamate | Gene expression | Epidemiology | Analysis | Genetic research | Genetic aspects | Single nucleotide polymorphisms | Progesterone | Cancer | Cell proliferation | Transformation | Correlation | Estrogens | Melanocytes | Glutamic acid receptors | Single-nucleotide polymorphism | Kinases | Medical diagnosis | Metastases | Genotypes | Deoxyribonucleic acid--DNA | Patients | Genotyping | Breast | Mutation | Health risk assessment | Glutamic acid receptors (metabotropic) | Tumors | Deoxyribonucleic acid | DNA
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2019, Volume 380, Issue 25, pp. 2395 - 2405
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2008, Volume 72, Issue 4, pp. 1056 - 1063
Purpose To evaluate the prognostic value of triple-negative (TN) ER, PR, Her2/neu basal-like carcinoma of the breast, at the time of ipsilateral breast tumor... 
Radiology | Hematology, Oncology and Palliative Medicine | Breast conserving surgery | Prognosis | Triple negative | Local recurrence | Radiation | MOLECULAR SUBTYPES | SURGERY | MASTECTOMY | PATTERNS | ESTROGEN-RECEPTOR STATUS | BRCA1 | CHEMOTHERAPY | ONCOLOGY | RADIOTHERAPY | CONSERVING THERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Risk Assessment - methods | Humans | Middle Aged | Incidence | Neoplasms, Hormone-Dependent - genetics | Breast Neoplasms - therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Genetic Predisposition to Disease - epidemiology | Breast Neoplasms - epidemiology | Genetic Predisposition to Disease - genetics | Neoplasm Recurrence, Local - prevention & control | Mastectomy, Segmental - statistics & numerical data | Risk Factors | Neoplasms, Hormone-Dependent - epidemiology | Connecticut - epidemiology | Neoplasms, Hormone-Dependent - therapy | Phenotype | Breast Neoplasms - genetics | Radiotherapy, Adjuvant - statistics & numerical data | Neoplasm Recurrence, Local - genetics | Aged | Breast Neoplasms - diagnosis | Neoplasm Recurrence, Local - epidemiology | Longitudinal Studies | Cohort Studies | Medical colleges | Care and treatment | Genetic aspects | Breast cancer | Radiotherapy | Health aspects | Cancer | PATIENTS | MAMMARY GLANDS | RADIATION HAZARDS | METASTASES | CARCINOMAS | PHENOTYPE | RADIOLOGY AND NUCLEAR MEDICINE
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 11, pp. 1058 - 1059
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 405 - 411
Abstract Background Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new... 
pembrolizumab | triple-negative breast neoplasms | ONCOLOGY | anti-PD-1 | PD-L1 EXPRESSION | immunotherapy
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2002, Volume 8, Issue 3, pp. 670 - 678
Journal Article
Cancer Research, ISSN 0008-5472, 02/2018, Volume 78, Issue 4 Supplement, pp. OT3-05-10 - OT3-05-10
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 10/2019, Volume 105, Issue 2, pp. 267 - 274
To report 5-year outcomes of a phase 2 trial of hypofractionated whole breast irradiation (HF-WBI) completed in 3 weeks, inclusive of a sequential boost. Women... 
ADJUVANT CHEMOTHERAPY | IRRADIATION | ONCOLOGY | CONSERVING SURGERY | INTENSITY-MODULATED RADIOTHERAPY | LONG-TERM OUTCOMES | UK STANDARDIZATION | RANDOMIZED-TRIAL | FOLLOW-UP | CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CARCINOMA IN-SITU | Clinical trials | Carcinoma, Ductal | Radiotherapy | Radiation
Journal Article